Copeptin is an independent predictor of diabetic heart disease and death

American Heart Journal

Volumn 169, Issue 4, 2015, Pages 549-556.e1

  Enhörning, Sofia ^a,b   Hedblad, Bo ^a,b   Nilsson, Peter M ^a,b   Engström, Gunnar ^a   Melander, Olle ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DEATH; FEMALE; HEART FAILURE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; INCIDENCE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SWEDEN; TRENDS;

BIOMARKERS; CAUSE OF DEATH; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; FEMALE; GLYCOPEPTIDES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SWEDEN;

EID: 84927570940     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.11.020     Document Type: Article

References (54)

1. S.J. Lolait, A.M. O'Carroll, and O.W. McBride Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus Nature 357 1992 336 339
2. J. Filep, and B. Rosenkranz Mechanism of vasopressin-induced platelet aggregation Thromb Res 45 1987 7 15
3. E.H. Ohlstein, and B.A. Berkowitz Human vascular vasopressin receptors: analysis with selective vasopressin receptor antagonists J Pharmacol Exp Ther 239 1986 737 741
4. P.D. Whitton, L.M. Rodrigues, and D.A. Hems Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions Biochem J 176 1978 893 898
5. S. Keppens, and H. de Wulf The nature of the hepatic receptors involved in vasopressin-induced glycogenolysis Biochim Biophys Acta 588 1979 63 69
6. C.L. Holmes, D.W. Landry, and J.T. Granton Science review: Vasopressin and the cardiovascular system. Part 1 - receptor physiology Crit Care 7 2003 427 434
7. E.A. Abu-Basha, S. Yibchok-Anun, and W.H. Hsu Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas Metabolism 51 2002 1184 1190
8. N.G. Morgenthaler, J. Struck, and C. Alonso Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin Clin Chem 52 2006 112 119
9. S. Enhorning, T.J. Wang, and P.M. Nilsson Plasma copeptin and the risk of diabetes mellitus Circulation 121 2010 2102 2108
10. S. Enhorning, L. Bankir, and N. Bouby Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort Int J Obes 37 2013 598 603
11. N.G. Morgenthaler Copeptin: a biomarker of cardiovascular and renal function Congest Heart Fail 16 Suppl. 1 2010 S37 S44
12. B. Stoiser, D. Mortl, and M. Hulsmann Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure Eur J Clin Invest 36 2006 771 778
13. S.R. Goldsmith Congestive heart failure: potential role of arginine vasopressin antagonists in the therapy of heart failure Congest Heart Fail 8 2002 251 256
14. S.A. Urwyler, P. Schuetz, and F. Fluri Prognostic value of copeptin: one-year outcome in patients with acute stroke Stroke 41 2010 1564 1567
15. M. Katan, F. Fluri, and N.G. Morgenthaler Copeptin: a novel, independent prognostic marker in patients with ischemic stroke Ann Neurol 66 2009 799 808
16. S.Q. Khan, O.S. Dhillon, and R.J. O'Brien C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study Circulation 115 2007 2103 2110
17. T. Reichlin, W. Hochholzer, and C. Stelzig Incremental value of copeptin for rapid rule out of acute myocardial infarction J Am Coll Cardiol 54 2009 60 68
18. T. Keller, S. Tzikas, and T. Zeller Copeptin improves early diagnosis of acute myocardial infarction J Am Coll Cardiol 55 2010 2096 2106
19. E. Giannitsis, T. Kehayova, and M. Vafaie Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction Clin Chem 57 2011 1452 1455
20. L.G. Mellbin, L. Ryden, and K. Brismar Copeptin, IGFBP-1, and cardiovascular prognosis in patients with type 2 diabetes and acute myocardial infarction: a report from the DIGAMI 2 trial Diabetes Care 33 2010 1604 1606
21. W. Fenske, C. Wanner, and B. Allolio Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus J Am Soc Nephrol 22 2011 782 790
22. G. Berglund, S. Elmstahl, and L. Janzon The Malmo Diet and Cancer Study J Intern Med 233 1993 45 51
23. M. Persson, B. Hedblad, and J.J. Nelson Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects Arterioscler Thromb Vasc Biol 27 2007 1411 1416
24. J.F. Ludvigsson, E. Andersson, and A. Ekbom External review and validation of the Swedish national inpatient register BMC Public Health 11 2011 450
25. National Board of Health and Welfare A finger on the pulse: Monitoring public health and social conditions in Sweden 1992-2002. Stockholm http://www.socialstyrelsen.se/publikationer2003/2003-118-16 2003 [27 Dec 2013]
26. L.A. Johansson, and R. Westerling Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics Int J Epidemiol 29 2000 495 502
27. G. Sarno, B. Lagerqvist, and J. Carlsson Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Int J Cardiol 167 2013 146 150
28. E. Ingelsson, J. Arnlov, and J. Sundstrom The validity of a diagnosis of heart failure in a hospital discharge register Eur J Heart Fail 7 2005 787 791
29. N. Hammar, L. Alfredsson, and M. Rosen A national record linkage to study acute myocardial infarction incidence and case fatality in Sweden Int J Epidemiol 30 Suppl. 1 2001 S30 S34
30. U. Lindblad, L. Rastam, and J. Ranstam Validity of register data on acute myocardial infarction and acute stroke: the Skaraborg Hypertension Project Scand J Soc Med 21 1993 3 9
31. F. Di Serio, V. Ruggieri, and L. Varraso Analytical evaluation of the Dade Behring Dimension RxL automated N-Terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010 Clin Chem Lab Med 43 2005 1263 1273
32. A. Grubb, U. Nyman, and J. Bjork Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine Scand J Clin Lab Invest 72 Feb 2012 73 77
33. M.I. Harris, R. Klein, and T.A. Welborn Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis Diabetes Care 15 1992 815 819
34. E. Meijer, S.J. Bakker, and N. Halbesma Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort Kidney Int 77 2010 29 36
35. E. Meijer, S.J. Bakker, and P.E. de Jong Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients Transplantation 88 2009 561 567
36. W.E. Boertien, E. Meijer, and D. Zittema Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease Nephrol Dial Transplant 27 2012 4131 4137
37. U. Alehagen, U. Dahlstrom, and J.F. Rehfeld Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure JAMA 305 2011 2088 2095
38. W.L. Miller, K.A. Hartman, and D.E. Grill Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: incremental prognostic value of novel biomarkers in heart failure Heart 98 2012 389 394
39. S.G. Wannamethee, P. Welsh, and P.H. Whincup N-terminal pro brain natriuretic peptide but not copeptin improves prediction of heart failure over other routine clinical risk parameters in older men with and without cardiovascular disease: population-based study Eur J Heart Fail 16 2014 25 32
40. A. Nitenberg, F. Paycha, and S. Ledoux Coronary artery responses to physiological stimuli are improved by deferoxamine but not by l-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors Circulation 97 1998 736 743
41. A. Nitenberg, S. Ledoux, and P. Valensi Impairment of coronary microvascular dilation in response to cold pressor-induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging Diabetes 50 2001 1180 1185
42. S.H. Alzahrani, and R.A. Ajjan Coagulation and fibrinolysis in diabetes Diab Vasc Dis Res 7 2010 260 273
43. D.S. Frankel, J.B. Meigs, and J.M. Massaro Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham Offspring Study Circulation 118 2008 2533 2539
44. J.E. Kaufmann, A. Oksche, and C.B. Wollheim Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP J Clin Invest 106 2000 107 116
45. H.C. Gerstein, M.E. Miller, and R.P. Byington Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2008 2545 2559
46. H.C. Gerstein, M.E. Miller, and S. Genuth Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 2011 818 828
47. R.W. Schrier, P. Gross, and M. Gheorghiade Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2006 2099 2112
48. M. Gheorghiade, M.A. Konstam, and J.C. Burnett Jr. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials JAMA 297 2007 1332 1343
49. J. Cederholm, K. Eeg-Olofsson, and B. Eliasson Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register Diabetes Care 31 10 2008 2038 2043
50. E. Lindholm, E. Agardh, and T. Tuomi Classifying diabetes according to the new WHO clinical stages Eur J Epidemiol 17 11 2001 983 989
51. J.F. Ludvigsson, E. Andersson, and A. Ekbom External review and validation of the Swedish national inpatient register BMC Public Health 11 2011 450
52. A finger on the pulse. Monitoring public health and social conditions in Sweden 1992-2002 (The report can be downloaded from http://www.socialstyrelsen.se/publikationer2003/2003-118-16) 2003 National Board of Health and Welfare Stockholm
53. L.A. Johansson, and R. Westerling Comparing Swedish hospital discharge records with death certificates: implications for mortality statistics Int J Epidemiol 29 3 2000 495 502
54. B. Wettermark, N. Hammar, and C.M. Fored The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months Pharmacoepidemiol Drug Saf 16 7 2007 726 735